Polymorphisms determine β-adrenoceptor conformation: implications for cardiovascular disease and therapy

Trends in Pharmacological Sciences

Volumn 30, Issue 4, 2009, Pages 188-193

  Ahles, Andrea ^a,b   Engelhardt, Stefan ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARVEDILOL;

ANAPHYLACTIC SHOCK; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CONFORMATIONAL TRANSITION; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC POLYMORPHISM; GLAUCOMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PREMATURE LABOR; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC AGENTS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; KINETICS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA;

EID: 62949132260     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.02.001     Document Type: Article

References (66)

1. Brodde O.E., and Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev. 51 (1999) 651-690
2. Lohse M.J., et al. What is the role of β-adrenergic signaling in heart failure?. Circ. Res. 93 (2003) 896-906
3. 1- and β-adrenoceptor signaling in the heart. Trends Pharmacol. Sci. 27 (2006) 330-337
4. 1-adrenoceptor: identification and rapid screening assay. Lancet 353 (1999) 897
5. 1-adrenergic receptor associated with survival in patients with heart failure. Eur. Heart J. 21 (2000) 1853-1858
6. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J. Mol. Cell. Cardiol. 31 (1999) 1025-1032
7. 1-adrenergic receptor. J. Biol. Chem. 274 (1999) 12670-12674
8. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J. Biol. Chem. 277 (2002) 30429-30435
9. 1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 39 (2002) 155-160
10. 2-adrenergic receptor signaling. J. Biol. Chem. 278 (2003) 10784-10789
11. 1-adrenoceptors. Br. J. Pharmacol. 142 (2004) 51-56
12. Small K.M., et al. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 381-411
13. Kirstein S.L., and Insel P.A. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol. Rev. 56 (2004) 31-52
14. Leineweber K., et al. β-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 1-22
15. 2-adrenoceptor gene polymorphisms. Pharmacogenet. Genomics 15 (2005) 267-275
16. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268 (1993) 23116-23121
17. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10483-10488
18. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33 (1994) 9414-9419
19. 1-adrenoceptor gene and aerobic power in coronary artery disease. Eur. Heart J. 27 (2006) 808-816
20. McCaffery J.M., et al. Variability within α- and β-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J. Hypertens. 20 (2002) 1105-1114
21. Filigheddu F., et al. Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade. Pharmacogenomics J. 4 (2004) 154-160
22. 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74 (2003) 44-52
23. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin. Sci. (Lond.) 99 (2000) 233-238
24. 1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. 27 (2004) 347-350
25. 1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 80 (2006) 23-32
26. 2-Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33 (1999) 1425-1430
27. 2-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J. Physiol. 546 (2003) 583-589
28. 2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345 (2001) 1030-1035
29. 2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin. Pharmacol. Ther. 78 (2005) 232-238
30. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1607-1612
31. 1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am. Heart J. 146 (2003) 106-109
32. 2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur. Heart J. 25 (2004) 1534-1541
33. 2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347 (2002) 1135-1142
34. 2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 113 (2006) 1842-1848
35. de Groote P., et al. The impact of β-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur. J. Heart Fail. 7 (2005) 966-973
36. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin. Pharmacol. Ther. 73 (2003) 366-371
37. 1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J. Am. Coll. Cardiol. 46 (2005) 2111-2115
38. 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9 (2003) 1300-1305
39. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11288-11293
40. 2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam. Clin. Pharmacol. 22 (2008) 107-125
41. 2-adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther. 117 (2008) 1-29
42. Strader C.D., et al. Structural basis of β-adrenergic receptor function. FASEB J. 3 (1989) 1825-1832
43. 2-adrenergic receptor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9276-9281
44. 2-adrenergic receptor. J. Biol. Chem. 275 (2000) 37779-37788
45. Strader C.D., et al. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264 (1989) 13572-13578
46. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
47. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
48. Salom D., et al. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16123-16128
49. 2-adrenergic G-protein-coupled receptor. Nature 450 (2007) 383-387
50. 2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
51. 2-adrenergic receptor function. Science 318 (2007) 1266-1273
52. 1-adrenergic G-protein-coupled receptor. Nature 454 (2008) 486-491
53. Gether U., and Kobilka B.K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273 (1998) 17979-17982
54. Reiter E., and Lefkowitz R.J. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17 (2006) 159-165
55. 2-adrenergic receptor. Evidence for ligand-specific conformational changes. J. Biol. Chem. 270 (1995) 28268-28275
56. 2-adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem. 276 (2001) 9279-9290
57. 2-adrenergic receptor. J. Biol. Chem. 276 (2001) 24433-24436
58. 2-adrenergic receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5997-6002
59. 2-adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279 (2004) 686-691
60. 2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280 (2005) 22165-22171
61. Förster T. Zwischenmolekulare Energiewanderung und Fluoreszenz. Annals of Physics (Leipzig) 2 (1948) 55-75
62. Giepmans B.N., et al. The fluorescent toolbox for assessing protein location and function. Science 312 (2006) 217-224
63. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117 (2007) 229-235
64. Griffin B.A., et al. Specific covalent labeling of recombinant protein molecules inside live cells. Science 281 (1998) 269-272
65. Hoffmann C., et al. A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat. Methods 2 (2005) 171-176
66. Dorsch, S. et al. Analysis of receptor oligomerization by FRAP microscopy. Nat. Methods. (in press)